Abstract
Treatments of obesity and type II diabetes target often gene functions involved in appetite-satiety, fat and carbohydrate metabolism or thermogenesis. None of these, have provided efficient drug therapy due to a large number of genes involved in weight and energy management, the redundancy of biochemical pathways and the environmental factors. Here I discuss a new approach based on studies of genes/proteins that are associated with human “lean or starvation" phenotype that became very rare in the course of evolution. This approach has led to the identification of the congenital enteropeptidase deficiency gene and the Andersonʼs Disease gene as a potential targets for obesity and type II diabetes treatment. The advantages of these targets are: 1) they are expressed exclusively in the intestine; 2) they are peripheral targets as opposed to systemic targets; 3) they are not redundant targets. These targets open new hopes for the development of novel drugs for the treatment of common metabolic syndrome.
Keywords: Diabetes treatment, drug discovery, lean phenotype, metabolic disorders, obesity, starvation phenotype, type II diabetes.
Current Pharmaceutical Biotechnology
Title:Rare Genetic Diseases with Human Lean and/or Starvation Phenotype Open New Avenues for Obesity and Type II Diabetes Treatment
Volume: 14 Issue: 13
Author(s): Itzik Harosh
Affiliation:
Keywords: Diabetes treatment, drug discovery, lean phenotype, metabolic disorders, obesity, starvation phenotype, type II diabetes.
Abstract: Treatments of obesity and type II diabetes target often gene functions involved in appetite-satiety, fat and carbohydrate metabolism or thermogenesis. None of these, have provided efficient drug therapy due to a large number of genes involved in weight and energy management, the redundancy of biochemical pathways and the environmental factors. Here I discuss a new approach based on studies of genes/proteins that are associated with human “lean or starvation" phenotype that became very rare in the course of evolution. This approach has led to the identification of the congenital enteropeptidase deficiency gene and the Andersonʼs Disease gene as a potential targets for obesity and type II diabetes treatment. The advantages of these targets are: 1) they are expressed exclusively in the intestine; 2) they are peripheral targets as opposed to systemic targets; 3) they are not redundant targets. These targets open new hopes for the development of novel drugs for the treatment of common metabolic syndrome.
Export Options
About this article
Cite this article as:
Harosh Itzik, Rare Genetic Diseases with Human Lean and/or Starvation Phenotype Open New Avenues for Obesity and Type II Diabetes Treatment, Current Pharmaceutical Biotechnology 2013; 14 (13) . https://dx.doi.org/10.2174/1389201015666140408124559
DOI https://dx.doi.org/10.2174/1389201015666140408124559 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pregnancy-Associated Plasma Protein-A and its Role in Cardiovascular Disease. Biology, Experimental/Clinical Evidences and Potential Therapeutic Approaches
Current Vascular Pharmacology Old But Good: Modified-Release Prednisone in Rheumatoid Arthritis
Reviews on Recent Clinical Trials Design and Evaluation of the Effectiveness of a Drug in Adhesive Transdermal Delivery System of Vildagliptin
Drug Delivery Letters Impact of Metabolic Surgery on Type 2 Diabetes Mellitus, Cardiovascular Risk Factors, and Mortality: A Review
Current Hypertension Reviews The Evil Axis of Obesity, Inflammation and Type-2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets PTP1b Inhibition, A Promising Approach for the Treatment of Diabetes Type II
Current Topics in Medicinal Chemistry Water Soluble Vitamins and their Role in Diabetes and its Complications
Current Diabetes Reviews Mild Mitochondrial Uncoupling as a Therapeutic Strategy
Current Drug Targets Role of Antioxidants, Essential Fatty Acids, Carnitine, Vitamins, Phytochemicals and Trace Elements in the Treatment of Diabetes Mellitus and its Chronic Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Delivery Methods of Camptothecin and Its Hydrosoluble Analogue Irinotecan for Treatment of Colorectal Cancer
Current Drug Delivery Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Inflammatory Risk Factors and Pathologies Associated with Alzheimers Disease
Current Alzheimer Research Do Rheumatoid Arthritis Patients Rate their Health Status Different than their Caregivers?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Myostatin Inhibition and Cardiometabolic Disorders
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Quality Evaluation of English Mobile Applications for Gestational Diabetes: App Review using Mobile Application Rating Scale (MARS)
Current Diabetes Reviews Editorial
Current Molecular Imaging (Discontinued) Are the Pleiotropic Effects of Telmisartan Clinically Relevant?
Current Pharmaceutical Design Treatment of Hypertensive Complications in Pregnancy
Current Pharmaceutical Design The Role of Nutrition During the COVID-19 Pandemic: What We Know
Endocrine, Metabolic & Immune Disorders - Drug Targets Endothelial Progenitor Cells as Potential Drug Targets
Current Drug Targets - Cardiovascular & Hematological Disorders